Post Marketing Study on Pluvicto in Korea
NCT06514521 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 278
Last updated 2025-12-30
Summary
Post marketing study on Pluvicto in Korea
Conditions
Interventions
- OTHER
-
Lutetium vipivotide tetraxetan
This is an observational study. There is no treatment allocation. The decision to initiate Lutetium vipivotide tetraxetan will be based solely on clinical judgement.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-04-18
- Primary Completion
- 2028-05-31
- Completion
- 2028-05-31
Countries
- South Korea
Study Locations
More Related Trials
-
Phase 2 Hypofractionation Study Using Proton Beam Therapy for Prostate Adenocarcinoma
NCT01709253 ·Status: COMPLETED ·Phase: NA
-
Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer
NCT06600802 ·Status: RECRUITING ·Phase: NA
-
Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer
NCT01938339 ·Status: UNKNOWN ·Phase: NA
-
Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
NCT04430192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
NCT06526299 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Prostate and pelvIs Versus prOsTate Alone Treatment for Locally Advanced Prostate Cancer
NCT01685190 ·Status: UNKNOWN ·Phase: PHASE2
-
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
NCT06972628 ·Status: RECRUITING ·Phase: PHASE2
-
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
NCT03511664 ·Status: COMPLETED ·Phase: PHASE3
-
Decipher Lethal Prostate Cancer Biology - Urine Metabolomics
NCT03237702 ·Status: RECRUITING ·Phase: NA
-
A Prospective Longitudinal Study of Health-Related Quality of Life in Men With Clinically Localized Prostate Cancer
NCT00777452 ·Status: COMPLETED
-
Focal Therapy for Localized Prostate Cancer
NCT03970863 ·Status: WITHDRAWN
-
Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer
NCT06461689 ·Status: COMPLETED
-
Immuno-molecular Approaches for Non-invasive Diagnosis of Prostate Cancer
NCT04702633 ·Status: COMPLETED
-
Immune Monitoring on Sipuleucel-T
NCT02237170 ·Status: COMPLETED
-
Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)
NCT06943495 ·Status: RECRUITING ·Phase: PHASE1
-
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
NCT04597411 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Comparison of Prostate Cancer-related Quality of Life in Sexually Active Men With Favourable Intermediate-risk Localised Prostate Cancer Treated With Total Prostatectomy or Focal HIFU
NCT06945172 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Effectiveness of Localized Prostate Cancer Treatments
NCT01492751 ·Status: ACTIVE_NOT_RECRUITING
-
Detection of Clinically Significant Prostate Cancer Using a Urinary Multimarker Sensor
NCT04825002 ·Status: UNKNOWN ·Phase: NA
-
SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
NCT07096999 ·Status: RECRUITING
-
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
NCT07054346 ·Status: RECRUITING ·Phase: PHASE1
-
68Ga-NOTA-RM26 PET/CT in Prostate Cancer Patients
NCT03164837 ·Status: UNKNOWN ·Phase: PHASE1
-
177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer
NCT05603559 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
New Treatment Modalities for Localized Prostate Cancer
NCT05523856 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluation of the Dose Received by the Prostate With in Vivo Dosimetry in Patients Treated With Daily IGRT Associated With IMRT Using Two Repositioning Techniques for Localized Prostate Cancer
NCT02279693 ·Status: TERMINATED ·Phase: NA